Johnson & Johnson transitions leadership of its innovative medicine unit

Johnson & Johnson confirmed on August 4 the transition of leadership for its Innovative Medicine division. Jennifer Taubert, who has served the company for over 21 years in senior roles, will step down from her post effective September 1, 2026. During her tenure leading the division, the Innovative Medicine business reached annual revenues exceeding $60 billion. Tom Cavanaugh will assume responsibility for the division, transitioning from his current role managing North America's commercial operations. Cavanaugh's background spans nearly three decades working across the biopharmaceutical sector, covering multiple therapeutic areas and regions. He will take a seat on the company's Executive Committee when he assumes his new position on September 1, 2026.

1. Jennifer Taubert retires from her position leading Innovative Medicine after 21+ years with the company, with departure date of September 1, 2026
2. Under Taubert's leadership, the Innovative Medicine business grew to over $60 billion in annual revenue
3. Tom Cavanaugh, currently Company Group Chairman for North America Innovative Medicine, will replace Taubert
4. Cavanaugh brings nearly three decades of biopharmaceutical experience spanning multiple therapeutic areas and geographies
5. Cavanaugh joins Johnson & Johnson Executive Committee effective September 1, 2026